Table 1.
Comparison of new and emerging factor VIII replacement products
| Factor name | Factor characteristic | Half-life (hours) | ABR | Treatment of bleeds | Reference |
|---|---|---|---|---|---|
| Octocog alfa (Advate®) | “Standard” factor concentrate, full-length molecule | 8–12 | 6.3 | 93% bleeding episodes controlled with one or two doses | 40 |
| Efmoroctocog alfa (Eloctate®) | B-domain deleted factor VIII-Fc fusion protein | 19.0 | Individualized prophylaxis 1.6, weekly prohy3.6 | 97.8% bleeds controlled with one or two doses | 27 |
| Rurioctocog alfa pegol (BAX 855, Adynovate®) | Full-length factor VIII, 20 kDa PEG | 14–19.6 | 1.9 | 95.9% bleeds controlled with one or two doses | 29 |
| Turoctocog alfa pegol (N8-GP) | B-domain truncated, 40 kDa PEG | 19 | 1.3 | TBD | 30 |
| Damoctocog alfa pegol (BAY 94-9027) | B-domain truncated, 60 kDa PEG | 19 | 1.9 | TBD | 31 |
| CSL 627 | Single-chain B-domain deleted | TBD | TBD | TBD | 28 |
Abbreviations: ABR, annualized bleeding rate; PEG, polyethylene glycol; TBD, to be determined.